Retatrutide's Seventh Circuit Hearing Was Held on 24 September — What Happens Next
TL;DR: The 7th Circuit heard Lilly's retatrutide biologic-classification appeal on 24 Sept 2026 — a ruling could take months.
What Happened on 24 September?
The US Court of Appeals for the Seventh Circuit heard oral arguments on 24 September 2026 in Eli Lilly and Company v. Kennedy, the case over whether retatrutide should be regulated as a biological product under a Biologics License Application (BLA), or as a conventional drug under a New Drug Application (NDA).[1] We previewed the hearing five days out, covering the arguments each side was expected to make.[2] This update covers what happened once the date actually arrived, and — just as importantly — what still hasn't.
As of publication, trade-press coverage confirms the hearing took place and addressed the same narrow procedural question flagged beforehand: whether the district court's September 2025 remand to the FDA was a sufficient remedy, or whether the appellate panel should go further and order a biologic classification outright.[3] A detailed account of the specific questions individual judges asked from the bench had not yet been published anywhere we could verify at the time of writing. The Seventh Circuit's standard practice is to post oral argument audio recordings to its public docket after the fact, which is the most reliable primary-source route to the actual exchange.[4]
Did the Panel Rule on the Day?
No, and it was never going to. Federal appellate panels hear oral argument and then take a case under advisement; they do not announce a decision from the bench. A three-judge panel typically deliberates for weeks to several months before circulating a written opinion, and a technical regulatory-classification question of this kind tends to sit toward the slower end of that range.[4]
What the hearing does not do. Holding oral argument doesn't change what retatrutide's completed Phase 3 trials reported, and it doesn't accelerate or delay the FDA's own, separate remand analysis, which continues in parallel regardless of when the panel rules.
That means the practical status quo from our pre-hearing preview still holds: the district court's underlying finding — that retatrutide does not meet the strict >40-amino-acid definition of a “protein,” but that the FDA's separate “analogous to a protein” test was applied arbitrarily — is not disturbed by anything that happened on 24 September itself.[5] Nothing changes for Lilly, the FDA, or retatrutide's regulatory status until a written opinion actually issues.
What Happens Between Now and a Ruling?
Two tracks continue to run independently. First, the Seventh Circuit panel deliberates on its own schedule; there is no statutory deadline forcing a decision by a particular date. Second, the FDA's own remand analysis — the agency-level reconsideration the district court ordered back in September 2025 — keeps proceeding separately, and could in principle produce a new agency determination before the court rules, or after.[5] Whichever lands first could still be challenged further by the losing side.
Lilly's own guidance, reported before the hearing, is that it can proceed with a marketing application under either application type if the classification question remains open when it files.[2] Nothing reported since 24 September changes that: the company's target of submitting a BLA in Q1 2027 is still the most recently confirmed public timeline, and this appeal is not reported to be a blocking dependency for that filing.
Also this week: EASD, 30 September
Six days after the hearing, Lilly presents full TRIUMPH-2 Phase 3 data for retatrutide at a dedicated symposium at the EASD annual meeting in Milan.[6] The two events are unrelated — nothing argued in Chicago changes the Milan data, and the Milan data is not evidence in the case — but they land in the same fortnight for a company juggling a completed Phase 3 package against an unresolved filing pathway.
Does This Affect UK Research-Reagent Supply?
No. This remains a US federal dispute over which American regulatory pathway a licensed pharmaceutical company must use to seek marketing approval for an investigational drug. It has no bearing on the UK regulatory position for research reagents, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK. Retatrutide remains unlicensed for human use everywhere, regardless of how the classification question or this hearing ultimately resolve.
Retatrutide is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- MDLinx. Inside retatrutide's black market, Eli Lilly's 6 new lawsuits, and a brewing FDA battle. September 2026. mdlinx.com
- Velox Peptides. See our pre-hearing preview (19 September 2026) for the arguments each side was expected to make.
- Reason. Can a New Weight Loss Treatment Escape the Legal and Regulatory Thicket? 10 September 2026. reason.com
- United States Court of Appeals for the Seventh Circuit. Operating procedures and public oral argument calendar. ca7.uscourts.gov
- Goodwin Law Insights. District Court Sets Aside FDA's Interpretation of "Analogous" to a Protein for Purposes of the "Biological Product" Category. October 2025. goodwinlaw.com
- Velox Peptides. See our EASD Milan symposium preview for the 30 September TRIUMPH-2 data presentation.
Frequently Asked Questions
Did the Seventh Circuit rule on retatrutide's classification on 24 September?
No. Federal appeals courts do not rule from the bench. The panel heard oral argument on 24 September 2026 in Eli Lilly and Company v. Kennedy and then took the case under advisement; a written opinion follows separately, typically weeks to several months later.
What is publicly known about what was argued at the hearing?
As of this article's publication, trade-press reporting confirms the hearing began on 24 September 2026 and covered the same underlying question previewed beforehand: whether the district court's 2025 remand to the FDA was a sufficient remedy, or whether the Seventh Circuit should go further and order a biologic classification outright. Detailed accounts of the judges' specific questions had not yet been published; the Seventh Circuit's own practice is to post argument audio recordings to its public docket.
Does the hearing change Lilly's Q1 2027 BLA filing target?
Not based on anything reported so far. Lilly has previously said it can proceed with a marketing application under either a Biologics License Application or a New Drug Application if the classification question is still unresolved when it files, so the pending appeal is not reported to be delaying the underlying regulatory submission.
Is this related to Lilly's EASD data presentation on 30 September?
No. The two events are legally and scientifically unconnected. The Seventh Circuit hearing concerns which US regulatory pathway applies to retatrutide's marketing application; Lilly's 30 September EASD symposium in Milan concerns clinical trial data. Nothing argued in the appeal changes the trial results, and the trial data is not evidence in the case.
Does this litigation affect UK research-reagent supply of retatrutide?
No. This is US federal litigation over which American regulatory pathway a licensed pharmaceutical company must use for an investigational drug. It has no bearing on the UK regulatory position for research reagents under the Human Medicines Regulations 2012. Velox Peptides supplies retatrutide as an HPLC-verified in vitro research reagent only, a status unrelated to this litigation. Order for research →